Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V117957 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome
NCT06285214Phase 1Completed
- Sponsor
- Imbrium Therapeutics
- Start
- May 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS) comparing V117957 Sequence with Placebo Sequence (2 arms). Primary endpoint: Change From Baseline for Worst Bladder Pain/Discomfort Scores Overnight / Over-the-day at 8 weeks. Started May 2022; status: completed.
02
Drugs
sunobinop
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on NCT06285214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285214.